Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celevac is a brand name for methylcellulose, a bulk-forming agent used to manage various gastrointestinal conditions. As a hydrophilic semi-synthetic polymer derived from cellulose, it works by absorbing water in the gastrointestinal tract, swelling to increase stool bulk and soften consistency. This mechanical action helps regulate bowel function, making it effective for both constipation and diarrhoea. It is indicated for irritable bowel syndrome (IBS), diverticular disease, and ulcerative colitis, and has also been used as an appetite suppressant for obesity management. In the UK, it was evaluated in the MIBS Trial for IBS but was discontinued from the market in January 2021.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylcellulose (Amdipharm).